Abstract:Background: Lung cancer patients who received lobectomy are at high risk of developing postoperative pulmonary complications. Clinical factors have been investigated to predict high risk patients; however, additional predictors are needed to accurately and reliably evaluate risk. Evidence has shown a relationship between the JAK-STAT pathway with pulmonary inflammation and lung injuries. Methods: We conducted a two stage discovery-validation study to evaluate the associations between genetic variations in JAK-STAT signaling pathway and the risk of developing postoperative pulmonary complications following lobectomy. A total of 223 SNPs from 27 genes were genotyped and analyzed in 264 early stage non-small cell lung cancer (NSCLC) patients who received lobectomy. Twelve significant (P<0.05) SNPs were then validated in additional 264 NSCLC patients. Results: Four SNPs showed a consistent effect in both discovery and validation populations and had a pooled p value < 0.05. Among them, PIAS3:rs10910829 was significantly associated with increased risk of developing complications in both the discovery (OR=1.78, 95%CI=1.16-2.74, P=0.008) and validation (OR=1.52, 95%CI=1.03-2.25, P=0.036) populations. PIAS2:rs9304337 was associated with decreased risk in the discovery set (OR= 0.45, 95%CI=0.21-0.95, P=0.037) and reached borderline significance (OR=0.53, 95%CI=0.26-1.05, P=0.071) in the validation set. A dose-response effect of increasing risk of developing complications with increasing number of unfavorable genotypes each patient carried was identified in the discovery population. Those with the highest number of unfavorable genotypes had an 8.82-fold increase (95% CI= 2.58-30.18) in risk compared to those with the lowest number. This effect was replicated in the validation population (P<0.001). A significant improvement in discriminatory ability was observed with the addition of the four genetic loci identified in our study to the epidemiological/clinical-based receiver operating characteristic curve in predicting the risk of developing complications. The area under the curve (AUC) was increased 8% from 0.68 for the initial model to 0.76 with the genetic variables. Bootstrap resampling internally validated the significance of this AUC difference (ΔAUC=0.024-0.129) and this improvement was replicated in the validation dataset. Conclusions: We identified genetic variations in the JAK-STAT pathway associated with risk of developing postoperative pulmonary complications in NSCLC patients. These biomarkers could be translated into the clinic to assist in identifying surgical patients who are at higher risk of developing pulmonary complications. Citation Format: Xia Pu, Michelle A.T. Hildebrandt, Jae Y. Kim, Yuanqing Ye, Ara A. Vaporciyan, Arlene M. Correa, Stephen G. Swisher, Jack A. Roth, Xifeng Wu. Genetic variations in the JAK-STAT pathway are associated with postoperative pulmonary complications after lobectomy in lung cancer patients. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B91.

Genetic Variation In The P38 Signaling Pathway As Markers For Postoperative Pulmonary Complications In Lung Cancer Patients

Abstract 4663: Genetic Variation in the P38 Signaling Pathway As Markers for Postoperative Pulmonary Complications in Lung Cancer Patients

Genetic Variation in the TNF/TRAF2/ASK1/p38 Kinase Signaling Pathway As Markers for Postoperative Pulmonary Complications in Lung Cancer Patients

Abstract B91: Genetic Variations in the JAK-STAT Pathway Are Associated with Postoperative Pulmonary Complications after Lobectomy in Lung Cancer Patients

The Long-Term Impact of Postoperative Pulmonary Complications after Video-Assisted Thoracic Surgery Lobectomy for Lung Cancer

Variations in the Vascular Endothelial Growth Factor Pathway Predict Pulmonary Complications.

Inflammatory Gene Polymorphisms Influence Risk of Postoperative Morbidity after Lung Resection

Abstract 4662: Genetic Predictors of Clinical Outcomes for Patients with Non-Small Cell Lung Cancer

Genetic Variants in Cytokine Signaling Pathways and Clinical Outcomes in Early-Stage Lung Cancer Patients

Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.

Abstract 1728: Genetic Variations in Epidermal Growth Factor Receptor Pathway Predict Recurrence and Response to Chemotherapy in Early Stage Non-Small Cell Lung Cancer

Association of Genetic Variations in Dna-Methyltransferases, Histone-Methyltransferases, and Methylated Dna-Binding Proteins with Recurrence and Survival in Early-Stage Non-Small Cell Lung Cancer Treated with Surgery Alone or Surgery and Chemotherapy.

Preoperative Pulmonary Function Correlates with Systemic Inflammatory Response and Prognosis in Patients with Non-Small Cell Lung Cancer: Results of a Single-Institution Retrospective Study

[Classification and Risk-factor Analysis of Postoperative Cardio-pulmonary Complications after Lobectomy in Patients with Stage I Non-small Cell Lung Cancer]

The P38α Rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.

Inflammation-related Genetic Variants Predict Toxicity Following Definitive Radiotherapy for Lung Cancer.

Peripheral Cytokines Are Not Influenced by the Type of Surgical Approach for Non-Small Cell Lung Cancer by Four Weeks Postoperatively

Genetic Variations In Apoptosis Pathway Are Associated With Survival In Late Stage Non-Small Cell Lung Cancer

Genetic Variants In Inflammation-Related Genes Are Associated With Radiation-Induced Toxicity Following Treatment For Non-Small Cell Lung Cancer

PI3K/PTEN/AKT/mTOR Pathway Genetic Variation Predicts Toxicity and Distant Progression in Lung Cancer Patients Receiving Platinum-Based Chemotherapy.